PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 70 filers reported holding PRELUDE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $73 | -23.2% | 19,122 | -5.0% | 0.00% | – |
| Q1 2024 | $95 | +10.5% | 20,122 | 0.0% | 0.00% | – |
| Q4 2023 | $86 | +38.7% | 20,122 | -0.1% | 0.00% | – |
| Q3 2023 | $62 | -31.1% | 20,149 | +0.7% | 0.00% | – |
| Q2 2023 | $90 | – | 20,000 | +21639.1% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 92 | -98.2% | 0.00% | – |
| Q1 2022 | $34,000 | -69.9% | 4,992 | -45.1% | 0.00% | – |
| Q4 2021 | $113,000 | -60.4% | 9,092 | -0.2% | 0.00% | – |
| Q3 2021 | $285,000 | +9.6% | 9,109 | +0.4% | 0.00% | – |
| Q2 2021 | $260,000 | -33.3% | 9,075 | +0.8% | 0.00% | – |
| Q1 2021 | $390,000 | -24.3% | 9,000 | +25.0% | 0.00% | -100.0% |
| Q4 2020 | $515,000 | – | 7,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,039,691 | $66,362,000 | 1.23% |
| Baker Brothers Advisors | 10,123,824 | $66,918,000 | 0.44% |
| HHLR ADVISORS, LTD. | 583,333 | $3,856,000 | 0.10% |
| CAXTON ASSOCIATES LP | 85,992 | $568,000 | 0.08% |
| Virtus ETF Advisers LLC | 24,180 | $160,000 | 0.06% |
| GSA CAPITAL PARTNERS LLP | 54,173 | $358,000 | 0.05% |
| DENALI ADVISORS LLC | 8,200 | $54,000 | 0.03% |
| PDT Partners, LLC | 12,641 | $84,000 | 0.01% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2,402,595 | $15,881,153,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 36,949 | $244,000 | 0.01% |